FAM197Y6

Across TCGA pan-cancer cohorts, FAM197Y6 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated FAM197Y6 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher FAM197Y6 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM197Y6 expression acts as an unfavorable survival marker, although some lineages such as TGCT and SKCM show a favorable association.

LIHC, PAAD, and HNSC are the cancer types where FAM197Y6 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	All	0.134	0.567	<.001	108	view →
PAAD	OS	Tertile	All	0.028	0.614	<.001	72	view →
HNSC	OS	Tertile	II,III,IV	0.393	0.678	.002	69	view →
KIRC	OS	Tertile	All	0.723	0.890	.001	48	view →
STAD	OS	Tertile	All	0.460	0.733	.017	36	view →
ESCA	DFS	Tertile	II,III,IV	0.213	0.525	.035	18	view →
TGCT	DFS	Tertile	All	0.915	0.626	.040	18	view →
SKCM	DFS	Tertile	All	0.647	0.199	.044	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

FAM197Y6–LIHC (DFS)

Open the LIHC breakdown →